Antimicrobial Resistance and Human Health

Prevention Cannot Wait

Antimicrobial resistance, usually shortened to AMR, is already changing how healthcare professionals prevent and treat infection. AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines designed to control them, making infections harder to treat and increasing the risk of serious illness, spread and death. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

Antibiotics have transformed modern medicine, but their effectiveness cannot be taken for granted. Protecting them requires responsible prescribing, accurate diagnosis, infection prevention and innovation in the tools available to clinicians and healthcare settings.

What AMR means for people

AMR does not mean that a person becomes resistant to antibiotics. Instead, the microorganisms causing an infection develop ways to survive treatment. A standard medicine may no longer work as expected, leaving clinicians with fewer options and sometimes requiring more complex, costly, even toxic alternatives. https://www.cdc.gov/antimicrobial-resistance/about/index.html

This has implications far beyond the treatment of everyday infections. Reliable antimicrobials support safe surgery, cancer care, transplants, intensive care, caesarean sections and the treatment of people with weakened immune systems. When resistant infections become more common, these important aspects of modern healthcare carry greater risk. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

The scale of the challenge is significant. The World Health Organization estimates that bacterial AMR was directly responsible for 1.27 million deaths globally in 2019 and associated with 4.95 million deaths. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

How resistance develops and spreads

Resistance is a natural, evolutionary biological process, but human activity can accelerate it. Every time an antimicrobial is used, susceptible microorganisms are more likely to be eliminated while those with resistance traits may survive and multiply. The rate at which bacterial multiplication takes place exacerbates this resistance very swiftly indeed.

Key contributors include:

•         Antibiotics being prescribed or used when they are not needed, including for viral illnesses that antibiotics cannot treat.
•         Incorrect dose, duration or medicine choice.
•         Patients sharing medicines, using leftover antibiotics or stopping prescribed treatment without clinical advice.
•          Delays in identifying the cause of an infection, which can lead to broad treatment before targeted treatment is possible.
•          Transmission of resistant microorganisms in hospitals, care homes, clinics and community settings.
•          Gaps in hygiene, cleaning, environmental decontamination, hand hygiene and infection-control procedures.
  

Resistant microorganisms can spread between people, animals and the environment. Prevention therefore needs to work across healthcare, communities, food systems and environmental settings, often described as a One Health approach. https://www.cdc.gov/antimicrobial-resistance/causes/index.html

Prevention is central to the AMR response

Reducing unnecessary antimicrobial use is vital, but this must sit alongside robust infection prevention and control. Avoiding infection in the first place means fewer people need antimicrobial treatment, lowering the opportunity for resistance to develop and spread.

Practical prevention measures include:

•          Maintaining good hand hygiene in healthcare, workplaces and at home.
•          Cleaning and disinfecting frequently touched surfaces and shared equipment appropriately.
•          Following established infection-prevention procedures in clinical and care environments.
•          Using vaccines where recommended and appropriate.
•          Supporting good respiratory hygiene, safe food handling and effective wound care.
•          Testing and diagnosing infections accurately, so treatment can be targeted where antimicrobials are genuinely needed.
•          Taking prescribed antimicrobials exactly as directed and never using medicines prescribed for someone else.

The World Health Organisation identifies infection prevention, access to quality diagnosis and appropriate treatment, plus surveillance and innovation, as core priorities for tackling AMR. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

Supporting infection control in human health

For hospitals, clinics, dental practices, care settings, laboratories and other professional environments, surface hygiene and sterilisation support the wider infection-control plan. Day-Impex’s Human Health collection includes surface disinfectants, hand-hygiene products and medical sterilisation solutions designed for professional healthcare and clinical settings.

These products (as with all biocides) should be used in line with their labels, technical guidance and local infection-control procedures. They are not a replacement for clinical judgement, diagnosis or antimicrobial stewardship, but appropriate cleaning and disinfection can help reduce the environmental spread of pathogens and support safer care environments.

A successful programme also needs consistency. Staff training, clear cleaning schedules, correct product dilution and contact times, suitable PPE, audit trails and regular review all help turn infection-prevention policy into reliable everyday practice.

Innovation needs collaboration

The response to AMR also depends on new diagnostics, vaccines and anti-infective technologies reaching the people and services that need them. Faster, more accurate diagnostics can help clinicians identify infections and make better-informed treatment decisions, reducing unnecessary use of broad-spectrum medicines.

Igniting Transformative Medicine 2026 is focused on accelerating the AMR response by bringing together healthcare leaders, researchers, innovators, industry, funders, regulators and other stakeholders. The London event, scheduled for 26 November 2026, will explore the development, funding, regulation and adoption of next-generation diagnostics, vaccines and anti-infectives.

A shared responsibility

Although AMR can feel like a global challenge beyond the control of any one person or organisation, progress is built through many everyday decisions such as; prescribing carefully, taking medicine correctly, preventing infections, maintaining high hygiene standards, and supporting innovation.

Healthcare providers, patients, care settings and suppliers all have a role to play and by combining responsible antimicrobial use with strong infection prevention and practical hygiene measures, we can help preserve effective treatment options for the people who need them.